The AI & Digitisation Zone will be hosted in the exhibition area and will serve as the central hub for AI-driven drug discovery, digital R&D, and next-generation platform technologies, bringing together innovators such as Recursion, Iktos, Structural Genomics Consortium, and other leaders across AI discovery platforms, cloud infrastructure, automation, bioinformatics, digital biology, academic hubs, and strategic pharma tech partners. This interactive space will feature poster presentations, live demos, and short tech talks, alongside an AI Networking Lounge and a coffee cart to foster meaningful connections and collaboration.

Experience Berlin like never before with our VR Formula One racing tour, followed by an evening of drinks, wine tasting, and invite-only exclusive dinner. Connect with peers, unwind, and enjoy the city’s sights in a relaxed, social setting.

Samir Mitragotri,
Professor, Harvard University 

Professor Mitragotri is a globally recognised innovator in drug delivery and bioengineering. He is a member of the National Academy of Engineering, National Academy of Medicine, and American Academy of Arts & Sciences, and has received top honours including the Controlled Release Society Founders Award and the AAPS Distinguished Scientist Award. His pioneering work in nanoparticles, microneedles, and targeted therapies continues to transform how drugs reach their targets. 

Shalini Andersson,
Vice President, RNA Gene Cell Therapy, AstraZeneca

Shalini leads targeted drug delivery and nucleic acid therapeutics in cardiovascular, renal, and metabolic diseases. A former Associate Professor at University of Linköping, she holds a PhD, 60+ publications, 5 patents, and serves on the boards of the Oligonucleotide Therapeutics Society and OligoNova. 

Closed-door sessions offer an exclusive space for candid, off-the-record discussions. Connect with peers, share insights, and tackle the industry’s toughest challenges. Designed for executives shaping the future of the sector:

• Brain-Targeted Drug Delivery For Neurodegenerative Therapies

• Advancing Oligonucleotide Delivery: From Molecular Design To Scalable, Clinically Viable Modalities 

Join senior leaders for candid, high-impact discussions shaping the future of drug development. Explore patient-centric product design, innovative delivery approaches, and ethical, non-animal strategies for safer, more effective therapies. These sessions are your chance to connect, debate, and influence the next generation of drug discovery and delivery breakthroughs:  

• Exploring Alternative Routes Of Administration For Biologics Beyond IV

• NAMS Approaches For Ethical Drug Development 

Dive into the future of peptide therapeutics with “Overcoming Scientific And Technological Challenges Of Formulating Oral GLP-1 Therapies” This high-impact panel tackles the scientific and technological hurdles of oral GLP1 development—from absorption, stability, and bioavailability to patient-centric design and delivery across the blood-brain barrier. Explore cutting-edge formulation strategies, emerging platforms, and translational approaches that are shaping the next generation of oral peptide therapies.